



# Sorelex

STEP OUT OF INFECTION

# Sorelex

## KEY PROPERTIES



- DESIGNED TO

Clean and deslough infected wounds  
& initiate the healing process using biological means

- MARKET SEGMENT

Healthcare professionals avoiding use of silver based products

- CLASSIFICATION

Medical device class III

# Sorelex

## INDICATION



- Venous, diabetic and pressure ulcers
  - Traumatic and surgical wounds
  - Infected wounds or wounds at risk of infection
  - Wounds with moderate- to- high levels of exudate
- 
- Sorelex is not indicated for dry wounds

# Sorelex

PRODUCT DESIGN



## ACTIVE LAYER

Specially processed combination of OCTENIDINE AND HYALURONIC ACID, having both antimicrobial and biological effect

## DESLOUGH LAYER

Attracts wound slough which is removed during wound redressing

## TRANSMISSION LAYER

Absorbs and leads the excessive exudate out of the wound into a secondary dressing

# ACTIVE LAYER

## FAVORABLE EFFECT ON THE WOUND BED

- Creates a gell in contact with the wound exudate
- Keeps the wound in the moist environment
- Gently sticks to the wound bed and thus perfectly copies shape of the wound

# ACTIVE LAYER


## BIOLOGICAL EFFECT OF SODIUM HYALURONATE

- Substance natural to human body, component of ECM
- Regulates inflammation and sets up correct healing processes
- Creates natural, moist environment favorable for migration and proliferation of skin cells



# ACTIVE LAYER

## ANTIMICROBIAL EFFECT OF OCTENIDINE

- Broad spectrum of antimicrobial efficacy against Gram-positive and Gram-negative bacteria and fungi.
  - Not absorbed into systemic circulation
  - Low cytotoxicity to fibroblasts and other cells
- 



**CLINICAL TRIAL RESULTS**



# Clinical trial

Open Labelled, Multicentre Study in Patients with Chronic, Infected Wounds

Length of the study

6 weeks

Number of dressing changes

3x per week

Average wound duration 103 wks

Wounds enroled in the study

Diabetic ulcer 6

Leg ulcer 36

Mixed ethiology 5

TOTAL NO. 47

# Clinical trial

## OBJECTIVES OF THE STUDY

Wound dimension changes

Signs of infection

Changes in wound bed tissue

Changes in exudate level


Overall opinion of investigators on Sorelex

# Clinical trial results


## WOUND DIMENSION CHANGES

AVERAGE WOUND SURFACE  
at screening  
31,14 cm<sup>2</sup>

AVERAGE WOUND SURFACE  
at final visit  
15,19 cm<sup>2</sup>



# Clinical trial - RESULTS




38 % patients with visible signs of infection

(bleeding tissue, malodour, pocketing, bridging, abscess, local heat, etc)

No wound deterioration due to the infection in patients without visible signs of infection


# Clinical trial results

## CHANGES IN WOUND BED TISSUE



# Clinical trial results


## CHANGES IN WOUND BED TISSUE



# Clinical trial results


## CHANGES IN EXUDATE LEVELS

screening



■ none ■ low ■ moderate

week 6



■ none ■ low ■ moderate

# Clinical trial - RESULTS

## OVERALL RESPONSE TO SORELEX IN COMPARISON WITH PREVIOUS TREATMENT

RESPONSE TO PREVIOUS TREATMENT			RESPONSE TO SORELEX			
			SIGNIFICANT IMPROVEMENT	IMPROVEMENT	NO CHANGE	WORSENING
WORSENING	6	→	3	2	1	0
NO CHANGE	17	→	8	6	3	0
IMPROVEMENT	24	→	17	7		0

Previous treatment: Acticoat, Actisorb Plus, Cutimed Sorbact, Dermacyn, Mepilex Ag, Aquacel Ag, Nugel, Inadine, Tender Wet, Mepitel, silver alginates, PHMB



# Clinical trial - RESULTS

## SUBJECTIVE EVALUATION OF SORELEX MADE BY INVESTIGATORS

### WOUND HEALING EFFECT

(1- no wound healing, 8 - extremely good)



### SPEED OF THE HEALING

(1- extremely slow, 8 - extremely fast)



### BENEFICIAL EFFECT IN GENERAL

(1-extremely low, 8 – extremely high)



# Sorelex

STEP OUT OF INFECTION



- Broad spectrum of antimicrobial activity
- Biactive support of the healing process
- Safe and friendly for skin cells